Business
OBD in San Francisco for JPM Healthcare conf 2023
OBD in San Francisco for JPM Healthcare conf 2023.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n Oxford BioDynamics in San Francisco for\nthe 41st Annual J.P. Morgan Healthcare Conference\n \n \n \n \n \n Oxford, UK - 19 December 2022 -\n Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announced that its senior leadership will be in San Francisco during the 41st Annual J.P. Morgan Healthcare Conference, Jan 9-12 2023.\n \n \n OBD concluded a successful year in 2022, with its flagship EpiSwitch Checkpoint Inhibitor Response Test (CiRT) made available and in commercial use both in the UK and the US, where it also received a unique reimbursement code by the American Medical Association's CPT (Current Procedural Terminology) Editorial Board. The year has also seen compelling data and clinical utility described by renowned oncologists with pharma collaborators at leading global conferences, such as ASCO 2022 and ESMO 2022. \n \n \n OBD's EpiSwitch platform was developed to diagnose patients and determine how individuals might respond to disease or treatment, leveraging the Company's deep understanding of how the 3D configuration of the genome plays a crucial role in gene regulation. The Company's flagship product, the EpiSwitch CiRT, is a first-of-its-kind precision medicine blood test that predicts a cancer patient's likely response to Immune Checkpoint Inhibitors (ICIs), including widely used anti-PD-L1 and anti-PD-1 therapies. Despite their potential benefit, it is estimated that 70%+ of patients treated with an ICI will not have a clinical response.\n \n \n OBD's CEO Dr Jon Burrows and CSO Dr Alexandre Akoulitchev will be attending meetings to discuss details of the unique EpiSwitch platform, as well as future plans for its use. If you would like to meet the team, please contact\n \n [email protected]\n \n .\n \n -Ends-\n \n For further details please contact:\n \n \n \n \n \n \n \n Oxford BioDynamics Plc\n \n \n \n Jon Burrows, CEO\n \n \n Paul Stockdale, CFO\n \n \n \n \n \n \n \n +44 (0)1865 518910\n \n \n \n \n \n \n \n Shore Capital\n \n \n \n \n Nominated Adviser and Broker\n \n \n \n Stephane Auton\n \n \n John More\n \n \n \n \n \n \n \n +44 (0)20 7408 4090\n \n \n \n \n \n \n Instinctif Partners\n \n \n \n \n Tel: +44 (0)20 7457 2020\n \n \n...